| PRODUCT NAME | QUALITY GRADE | STATUS |
Ranolazine | In-House/ USP PF 44(3) | US DMF Filed EU ASMF Filed China NMPA DMF Filed |
| Pregabalin | IP/ USP/ Ph. Eur/ BP/ In-House | US DMF Filed China NMPA DMF Filed CEP Granted JDMF Filed KDMF Filed ANVISA DMF Filed |
| Sugammadex Sodium | In-House | EU ASMF Filed |
| Dolutegravir Sodium | In-House | WHO DMF Under Compilation |
| Levocetirizine DI-HCL | USP/IP/In-House | Validation Completed |
| Empagliflozin | In-House | In-House DMF Available |
| Ziprasidone DI-HCL | USP/IP | In-House DMF Available |
| Doxazosin Mesylate | USP/BP/In-House | In-House DMF Available |
| Alfuzosin HCL | USP/Ph.Eur | In-House DMF Available |
| Cetirizine DI-HCL | USP/Ph.Eur/IP/BP | In-House DMF Available |
| Prazosin HCL | USP/EP | In-House DMF Available |
| Silodosin | In-House | In-House DMF Available |
| Darunavir Ethanolate | In-House | Under Validation |
| Ziprasidone Mesylate Trihydrate | Ph.Eur/In-House | Under Validation |
| Sitagliptin Phosphate Monohydrate | USP/ Ph.Eur/ IP | Under Validation |
| Oclacitinib Maleate [VET] | In-House | Tech Pack Ready |
| Azilsartan Base | In-House | Tech Pack Ready |
| Sitagliptin HCL | In-House | Tech Pack Ready |
| Avibactam Sodium | In-House | Under Development |
| Azilsartan Medoxomil | In-House | Under Development |
| Bempedoic Acid | In-House | Under Development |
| Bilastine | In-House | Under Development |
| Candesartan Cilexetil | In-House | Under Development |
| Dabigatran Etexilate Mesylate | In-House | Under Development |
| Fosravuconazole | In-House | Under Development |
| Garenoxacin | In-House | Under Development |
| Pentosan Polysulfate Sodium | In-House | Under Development |
| Terazosin HCL | USP | Under Development |
